SIOP Education

Education forms a large part of our society’s vision and mission and we are very proud to be able to launch our first accredited online course to our community.

This is only a first step in harmonizing our educational offer and we will bring together more content over the coming months on a single platform.

This official knowledge portal of SIOP, will be become a powerful resource featuring a wide range of educational content developed by us over the years with access to hundreds of educational resources by topic, speaker, event including Congress Webcasts, Podcasts, eLectures, eCourses etc.

Stay tuned!

Background of Difficult-to-treat Cancers in Children

Despite the encouraging progress and success in the treatment of many childhood malignancies, cancer is a leading cause of death in childhood.
Further research is needed to expand the knowledge of the genetic modifications that drive malignant transformation and progression of other pediatric cancers in order to develop directed and less toxic therapies.
This course will give you an insight into the rapid advances in understanding of oncogenic drivers and the molecular profiling of cancers, and addressing novel and emerging treatments proving to be effective for difficult-to-treat cancers.

How to access the online course?

To get access to the Background of Difficult-to-treat Cancers in Children course:
1. Go to$siopce1
2. Log in or create a new account
3. Enter the accredited eLearning activity and start your learning experience!

What's in it for you?

After this course, participants will be able to:
  • Identify children with difficult-to-treat cancers who may benefit from targeted therapies
  • Estimate the percentage of children with cancer and specific cancer types whose cancer may respond to targeted therapies
  • Consider TRK fusion cancer as an example of the rapid progress in diagnosis, biology, and therapy for childhood cancer
  • Assess the impact of TRK fusion cancer drugs (e.g. larotrectinib, entrectinib) as examples of targeted therapy for people whose cancer is caused by specific genetic alterations


The content of this course was created in collaboration with Dr. Peter Adamson and Dr. Scott Howard.
We would like to sincerely thank Dr. Adamson and Dr. Howard for their time and commitment, and for sharing their professional expertise that has helped bring this content to life.

We would also like to use this opportunity to thank our Educational partner, Bayer, for their generous contribution and support of our activities.

This course is supported by an independent educational grant from Bayer.